Posted in FINANCE GSK Bolsters Vaccine Business With $3.3 Billion Deal for Affinivax May 31, 2022 The British pharmaceutical giant agreed to acquire the vaccine maker in a deal that would hand it a new vaccine technology targeting common bacterial diseases such as meningitis and pneumonia. …read more https://www.wsj.com/articles/gsk-bolsters-vaccine-business-with-3-3-billion-deal-for-affinivax-11653995677?mod=pls_whats_news_us_business_f